RFCA
BIO icon

R&F Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

R&F Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$523K Buy
+2,622
New +$505K 0.14% 236

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

R&F Capital Advisors's BIO Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Bio-Rad Laboratories Class A (BIO) in Q1 2017: 2,622 shares worth $523K. The stake represents 0.14% of the portfolio and ranks #236 among its holdings.

274 funds tracked by Wall St. Rank hold BIO as of Q1 2017.

  • R&F Capital Advisors held 2,622 shares of Bio-Rad Laboratories Class A worth $523K as of Q1 2017.
  • Bio-Rad Laboratories Class A was a new R&F Capital Advisors position in Q1 2017.
  • Bio-Rad Laboratories Class A made up 0.14% of R&F Capital Advisors's portfolio in Q1 2017, its #236 holding.
  • 274 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.